Galectin (GALT) news
Recent news
Galectin Therapeutics Inc: Q2 net loss per share $0.14 - SEC filing
Galectin Therapeutics Inc. (NASDAQ: GALT) reported a net loss applicable to common stockholders of $7.6 million, or $0.12 per share, for the quarter ended June 30, 2025, according to its Q2 2025 financial results. This represents a reduction in the net loss compared to the $12.4 million, or $0.20…
AInvest Wire · Aug 14, 2026Galectin Therapeutics - reaches agreement with FDA on primary endpoint and regulatory path for potential full approval of Belapectin
Galectin Therapeutics Inc. (NASDAQ: GALT) has reached alignment with the U.S. Food and Drug Administration (FDA) on the patient population for a registration trial for belapectin, its investigational galectin-3 inhibitor. The FDA provided a written response to the company’s Type C meeting request,…
AInvest Wire · Jun 23, 2026Galectin Therapeutics - to file Phase 3 protocol for belapectin in Q3 2026 - SEC filing
Galectin Therapeutics, Inc. (NASDAQ: GALT) has announced plans to file a Phase 3 clinical trial protocol for its lead drug candidate, belapectin, in the third quarter of 2026, according to recent SEC filings and company disclosures. The announcement follows continued positive data from the NAVIGATE…
AInvest Wire · Jun 23, 2026Damora Therapeutics Inc <DMRA.O>: TD Cowen initiates coverage with buy rating
TD Cowen has initiated coverage on Damora Therapeutics Inc (NASDAQ:DMRA), assigning the stock a "Buy" rating . This move aligns with a broader trend of increased analyst attention on the clinical-stage biotechnology firm, which has attracted multiple "Buy" ratings from other major firms in recent…
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.